366 results about "Binding peptide" patented technology

The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.

An MHCl binding peptide design method based on evolutionary information and a Transform neural network algorithm relates to the field of protein design, and comprises the following steps: S1, extracting evolutionary information features of alleles of MHCII molecules and binding core sequences of binding peptides corresponding to the alleles, S2, establishing a neural network model based on fusion of a convolution module and a Transform module, and S3, establishing a neural network model based on fusion of the convolution module and the Transform module, the method comprises the following steps: S1, extracting two frequency characteristic tensors from S11 and S12, taking the two frequency characteristic tensors extracted in S11 and S12 as double inputs, and finally obtaining probability distribution of 20 amino acids at each position of each sequence, and S3, according to an output result of a neural network model, carrying out random sampling according to the probability, and generating a binding core sequence of MHCII-peptide meeting target distribution. According to the method, evolutionary information such as sequence position amino acid frequency (first-order conservative analysis) and combined frequency (second-order conservative analysis) of amino acid pairs is introduced to design a new short peptide sequence, the problem that short peptides cannot be designed based on structures is solved, and the reliability of short peptide sequence design based on evolutionary information is provided.

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.

The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.

The invention discloses a decafluorobiphenyl-based Tat47-57 binding peptide, the amino acid sequence of the binding peptide is shown as SEQ ID NO.1 or SEQ ID NO.2, the fourth amino acid and the eighth amino acid of the SEQ ID NO.1 are bound through decafluorobiphenyl, and the fifth amino acid and the twelfth amino acid of the SEQ ID NO.2 are bound through decafluorobiphenyl. In particular, the decafluorobiphenyl-based Tat47-57 binding peptides (P3 and P6) are efficient CPPs, capable of delivering a variety of cargo molecules into the cytoplasm of mammalian cells. Meanwhile, decafluorobiphenyl cyclization plays a key role in cellular uptake and endosome escape. The two peptides P3 and P6 show remarkable cell permeability, and are speculated to enter cells through gridding protein dependent endocytosis. They also show efficient endosome escape ability, and have successfully applied P3 and P6 as CPPs to deliver phospholipid peptides and avidin.

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

The invention relates to the technical field of biological genetic engineering, in particular to construction of recombinant lactobacillus plantarum of an African swine fever virus antigen, and the method comprises the following steps: constructing a lactobacillus plantarum shuttle vector containing different ASFV antigen genes; and referring to a genome sequence of a Chinese isolate CADCHN09 of ASFV disclosed in GenBank. The method has the advantages that an inducer is not needed, antigen protein is efficiently expressed, the dendritic cell (DC) binding peptide for enhancing immune cell uptake and processing is subjected to fusion expression, the oral immunization mode is simple, mucosal immunity is stimulated, and ASFV infection is effectively prevented and controlled; probiotics, namely lactobacillus plantarum, which naturally exist in animal intestinal tracts and can be colonized and copied in digestive tracts for a long time are used as a carrier; key epitopes of proteins such as nucleocapsid protein p72, outer envelope protein CD2v, inner envelope protein p54, p22, pE199L and pE248R, which play an important role in adsorption, internalization, endocytosis and membrane fusion of ASFV, are preferably fused with dendritic cell binding peptide and then are displayed on the surface of lactobacillus plantarum.

The invention relates to a second antibody for resisting mouse IgG and rabbit IgG as well as a preparation method and application of the second antibody. The second antibody of the anti-mouse IgG and the rabbit IgG sequentially comprises an anti-mouse IgG nano antibody, a biotin fixed-point binding peptide fragment and an anti-rabbit IgG nano antibody from an amino terminal to a carboxyl terminal. According to the design of the second antibody of the anti-mouse IgG and rabbit IgG with a brand-new structure and the preparation method, high-efficiency expression is realized, the second antibody of the anti-mouse IgG and rabbit IgG capable of realizing fixed-point biotinylation is obtained, the second antibody can be further subjected to various modification reformation based on a biotin-streptavidin bridge, the preparation method of the second antibody of the polymerase labeled anti-mouse IgG and rabbit IgG is further developed, and the application of the second antibody of the polymerase labeled anti-mouse IgG and rabbit IgG is expanded. According to the method, the polymerase-labeled mouse-rabbit universal secondary antibody with similar affinity to mouse IgG and rabbit IgG is obtained, the preparation period of the secondary antibody can be shortened, the preparation process of the secondary antibody is simplified, the stability between batches is improved, and meanwhile, the dependence on experimental animals is reduced.

The application provides a recombinant fusion protein containing 1) an anti-PD-L1 antibody or an antigen-binding fragment thereof, and 2) an VEGF binding peptide, wherein the N-terminus of the heavy chain or the light chain of the anti-PD-L1 antibody or the antigen-binding fragment thereof is linked, via a linker, to the VEGF binding peptide. Also provided is a nucleic acid molecule for encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for preparing the recombinant fusion protein, and a method for treating a disease associated with PD-L1 and / or VEGF signaling using the recombinant fusion protein.

The invention provides a peptide fragment for modifying a Fe3O4 (at) Au magnetic nanoparticle and a preparation method of the Fe3O4 (at) Au magnetic nanoparticle, the peptide fragment is an alpha-peptide fragment 1 or / and a beta-peptide fragment 1, and the fragment of the peptide fragment is as shown in SEQ ID NO: 1. The method comprises the following steps: firstly, growing a layer of gold shell on the surface of Fe3O4 in situ to provide more modification sites, and then modifying PS binding peptide (PSBP) by using an Au-S bond to construct the PS NPs selective probe. The ultralow-concentration PS can be quantitatively detected only by monitoring the ultraviolet-visible absorption change of the probe. The peptide modified Fe3O4 (at) Au probe (Fe3O4 (at) Au-PSBP) has good linearity in a range of 0 to 80 pg mL <-1 >. The probe has been successfully applied to actual samples, such as bottled water, edible salt and milk. The adding standard recovery rate is 98.85%-112.10%, and the relative standard deviation (RSD) is 2.53%-13.80%. The provided Fe3O4 (at) Au-PSBP can be easily expanded to other types of NPs by simply replacing peptides, shows huge potential as a universal specific probe, and can sensitively and quickly detect low-concentration NPs in an actual sample.

The present invention relates to a conjugate for inhibiting viral replication, a preparation method therefor, and use thereof. The conjugate comprises a dimer or trimer of a portion that inhibits influenza virus neuraminidase (e.g. zanamivir, peramivir, oseltamivir, or an analog thereof), the dimer or trimer being conjugated to an Fc domain monomer, an Fc domain, an Fc-binding peptide, an albumin, or an albumin-binding peptide. The conjugate can be used to treat viral infections (e.g., influenza virus infections).

A Delta-Like Ligand 3 (DLL3) binding peptide having a binding specificity to human DLL3, comprising an amino acid sequence having at least 98%, 95%, or 92% of sequence identity to SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46.

The invention discloses a coupling drug of albumin binding peptide fused with a single-domain antibody and a preparation method and application thereof, and relates to the technical field of biological pharmacy, the coupling drug is obtained by fusing albumin binding peptide and the single-domain antibody to obtain fusion protein and coupling drug molecules with the fusion protein; the fusion form of the albumin binding peptide and the single-domain antibody comprises a single-target monoclonal antibody mode: the C terminal or the N terminal of the albumin binding peptide is fused with one single-domain antibody; in the single-target double-antibody mode, the C end and the N end of the albumin binding peptide are simultaneously fused with one single-domain antibody or are respectively fused with two same single-domain antibodies; and a double-target double-antibody mode: the C end and the N end of the albumin binding peptide are respectively fused with two different single-domain antibodies. By means of the characteristic of high-affinity binding of the albumin binding peptide and the serum albumin, the long-acting effect of the coupling medicine in vivo can be achieved, the effect that the coupling medicine is enriched to a tumor part in vivo in a targeted mode can be achieved, and the anti-tumor purpose is achieved.

The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.

The present invention discloses a method for predicting peptides that are capable of binding to HLA molecules that incorporate the crystal structure of HLA molecules. An improved HLA-specific peptide docking workflow is used to simulate the occupancy of a peptide on the binding pocket of an HLA molecule, and three models are trained to predict the binding of the peptide to HLA molecules. The results show that these models predict HLA-allele specific binding peptides with extremely high accuracy.

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

The invention discloses a time-space controllable T cell adapter based on a DNA nanostructure as well as a construction method and application of the time-space controllable T cell adapter, and belongs to the field of DNA nanotechnology. The T cell adapter comprises a six-spiral-bundle paper folding structure, and an internal functional layer and an external shielding layer which are assembled on the six-spiral-bundle paper folding structure; the six-spiral bundle paper folding structure is formed by assembling 63 staple chains and M13 in total; the internal functional layer comprises nucleic acid-antibody conjugates which are combined on four spiral extension sequences at the top and the bottom of the six-spiral bundle origami structure, and hand-in-hand palindromic sequences which are combined on two spiral extension sequences at the left side and the right side; the outer shielding layer comprises a C-chain modified serum albumin binding peptide and a chain I, and the chain I comprises a pH-responsive i-motif switch. The T cell adapter disclosed by the invention has the space-time control capability of pH response and the potential of inducing TCR clustering to enhance T cell activation, and has huge potential in the aspect of improving the safety and effectiveness of T cell immunotherapy.

The present disclosure relates to the use of DNA-peptide hybrid molecules to detect target molecules in a sample. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Kits comprising DNA-peptide hybrid molecules are also provided.

Disclosed herein are effector domains. The effector domains may be used with, for example, Cas proteins and CRISPR-Cas systems. The effectors may be used in combination with a Cas protein to form a fusion protein. The effectors may also be used in combination with an antibody that binds to a peptide epitope, wherein the peptide epitope is fused to a Cas protein. The compositions and methods comprising the effectors may be used to modulate gene expression.

The invention relates to the technical field of medicines, in particular to a polypeptide coupling medicine of a somatostatin receptor binding peptide coupling TLR agonist and a preparation method of the polypeptide coupling medicine. The polypeptide coupling medicine of the somatostatin receptor binding peptide coupling TLR agonist provided by the invention comprises at least one compound in a formula I-1 and a formula I-2 in the specification or a pharmaceutically acceptable salt of the compound. According to the polypeptide coupling drug based on the specific molecular structure provided by the invention, somatostatin receptor binding peptide is coupled with a TLR agonist, so that the polypeptide coupling drug not only has tumor tissue targeting property, but also can activate TLR7 and TLR8 receptors on cytoplasm endosomes in tumor tissues, exerts an anti-tumor immunostimulation effect, and has a good application prospect. Meanwhile, the immunotoxicity of blood and non-specific organs is lower.

Provided herein are antigen binding proteins (ABPs) that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets and methods of treating cancers and other diseases using the disclosed ABPs.

The present invention relates to an anti-apolipoprotein E4 (ApoE4) antibody and use thereof and, more specifically, to: an anti-ApoE4 antibody or an antigen-binding fragment thereof; a fusion in which the anti-ApoE4 antibody or an antigen-binding fragment thereof and one or more blood-brain barrier (BBB) receptor-binding peptides are bound; a method for preparing the fusion; and a composition for preventing or treating neurodegenerative diseases or metabolic diseases, comprising the anti-ApoE4 antibody or an antigen-binding fragment thereof, or the fusion.

A modular CRISPR-Cas system for ribonucleoprotein (RNP) delivery is provided, the CRISPR-Cas system comprising a CRISPR-Cas protein fused to a first binding peptide and a functional protein fused to a second binding peptide, where the first binding peptide and the second binding peptide are configured to bind to each other and define a binding peptide pair. Also provided are methods of assembling the CRISPR-Cas complexes for the delivery of ribonucleoprotein (RNP) and the CRISPR-Cas complexes, as well as the use of the modular CRISPR-Cas systems or CRISPR-Cas complexes for the modification of the genome of an organism.

Provided are an activity-regulatable IL-12 fusion protein and the use thereof. The fusion protein comprises a first structural unit, a second structural unit, and a third structural unit. The first structural unit is selected from a first Fc fragment, or a first antibody or an antigen-binding fragment thereof, wherein the first antibody or the antigen-binding fragment thereof has the binding activity to a tumor antigen or an immune checkpoint; the second structural unit is selected from a cleavable linker or a non-cleavable linker; and the third structural unit comprises an IL-12 cytokine or a functional fragment thereof. The second structural unit mediates the steric hindrance of the first structural unit to mask the activity of the IL-12 cytokine in the third structural unit, thereby reducing the toxic side effects of in-vivo use of the IL-12 cytokine. Compared with a wild-type IL-12, the fusion protein has the advantage of high safety, and can be further fused with an antibody Fab, scFv or VHH, an antigen-binding peptide or a recombinant protein, a polypeptide, etc. to obtain a multifunctional fusion protein that can be conditionally released and activated.

The present disclosure relates to compositions and methods for treating viral infections. Compositions and methods for treating viral infections include conjugates comprising a viral neuraminidase inhibitor (e.g., zanamivir, peramivir, or an analog thereof) linked to an Fc monomer, an Fc domain, and an Fc binding peptide, albumin, or an albumin binding peptide. In particular, the conjugates are useful in the treatment of viral infections (e.g., influenza virus infections).

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.

A method for generating binding peptides presented by any given Major Histocompatibility Complex (MHC) protein is presented. The method includes, given a peptide and an MHC protein pair, enabling a Reinforcement Learning (RL) agent to interact with and exploit a peptide mutation environment by repeatedly mutating the peptide and observing an observation score of the peptide, learning to form a mutation policy, via a mutation policy network, to iteratively mutate amino acids of the peptide to obtain desired presentation scores, and generating, based on the desired presentation scores, qualified peptides and binding motifs of MHC Class I proteins.

The invention relates to the technical field of health food, in particular to a selenium tea ethanol dehydrogenase activating peptide composition as well as a preparation method and application thereof. A response surface method is adopted to optimize a TSE-PP preparation process, affinity ultrafiltration and LC-MS / MS technologies are utilized to screen ADH binding peptides, and the action mechanism of the ADH binding peptides is researched through molecular docking and animal experiments. Experiments prove that the TSE-PP can promote ethanol metabolism, relieve liver cell injury, inhibit inflammatory response, relieve oxidative stress and improve liver lipid accumulation, the high-dose use effect is more remarkable, and a scientific basis is provided for application of the TSE-PP in the food with the function of dispelling the effects of alcohol and the nutrition fortified product. The invention discloses the preparation process of the TSE-PP and the anti-alcohol and liver protection effects of the TSE-PP, meanwhile, the TSE-PP has good food processing characteristics, and a theoretical basis and an experimental support are provided for production and application of the TSE-PP in functional foods.